Cerecin received US FDA clearance to study CER-0001 under an Investigational New Drug (IND) application for Infantile Spasms
07 déc. 2022 06h00 HE
|
Cerecin
The authorization of the IND for Infantile Spasms (IS) is the third for tricaprilin, with other INDs open in Alzheimer’s disease and migraineA pilot study of CER-0001 in IS is ongoing in Australia and...
Cerecin Announces Abstract on New Infantile Spasms Data Accepted for Oral Presentation at the International League Against Epilepsy EME Congress 2022
03 nov. 2022 07h00 HE
|
Cerecin
SINGAPORE and DENVER, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Cerecin, Inc. a clinical-stage biotechnology company pioneering innovative neurotherapeutics, today announced that a poster showcasing new...
Results of Pilot Study of CER-0001 in Migraine support advancement into a pivotal global Phase 2/3 study
31 oct. 2022 07h00 HE
|
Cerecin
Data from the RELIEF study, a pilot study assessing the safety and efficacy of the investigational compound CER-0001 in participants with migraine, showed a positive efficacy signal The outcome...
Cerecin appoints Dr. Marc Cantillon as Chief Medical Officer
10 oct. 2022 07h00 HE
|
Cerecin
Cerecin expands senior management team with appointment of Dr. Marc Cantillon as Chief Medical OfficerDr. Cantillon brings over 25 years experience in senior Central Nervous System (CNS) development...
Cerecin closes Series IIB financing to advance CER-0001 clinical programs and build pipeline in neuro-metabolism drug development
28 sept. 2022 06h00 HE
|
Cerecin
Series IIB Financing was supported by existing and new investors in South Korea.Proceeds strengthen Cerecin’s operating position to advance the clinical studies of CER-0001 in migraine and infantile...
Cerecin Announces Appointment of Milan Vinnola as General Counsel
14 déc. 2021 07h00 HE
|
Cerecin
DENVER and SINGAPORE, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Cerecin, a clinical-stage biotechnology company developing ketogenic agents as potential neurotherapeutics, today announced the appointment of...
Cerecin Enrolls First Patient in a Pilot Clinical Trial of Tricaprilin in the Treatment of Infantile Spasms
09 nov. 2021 07h00 HE
|
Cerecin
SINGAPORE and DENVER, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Cerecin, a clinical-stage biotechnology company developing ketogenic agents as potential neurotherapeutics, today announced the enrollment of...
Cerecin raises $40 Million Series II and IIA financing to support its programs in neurological disorders
19 oct. 2021 07h00 HE
|
Cerecin
Prominent banks and institutional investors from South Korea follow an earlier cornerstone investment from Cerecin’s long-term partner, Nestlé.Proceeds will be used to fund product and pipeline...
Julie Liu Joins Cerecin From Pfizer as New Vice President of R&D and Chemicals, Manufacturing and Controls
04 févr. 2021 06h00 HE
|
Cerecin
Colorado USA, Melbourne Australia, and Singapore, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Cerecin, Inc. a clinical-stage biotechnology company pioneering ketogenic neurotherapeutics, today announced the...
Cerecin Enrolls First Patient in a Phase 2 Pilot Clinical Trial of Tricaprilin for Migraine Prevention (the Relief Study)
17 déc. 2020 07h40 HE
|
Cerecin
Colorado, USA and Melbourne, Australia, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Cerecin, a biopharmaceutical company focused on brain therapeutics, announced the enrollment of the first patient in its...